{"id":63348,"date":"2026-04-16T21:11:06","date_gmt":"2026-04-16T13:11:06","guid":{"rendered":"https:\/\/flcube.com\/?p=63348"},"modified":"2026-04-16T21:11:08","modified_gmt":"2026-04-16T13:11:08","slug":"mabwell-bioscience-secures-second-nmpa-approval-for-denosu-chinas-first-xgeva-biosimilar-expanding-indication-to-bone-metastasis-and-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63348","title":{"rendered":"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China&#8217;s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma"},"content":{"rendered":"\n<p><strong>Mabwell (Shanghai) Bioscience Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>) has announced a second indication approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>Denosu<\/strong>, the country&#8217;s <strong>first biosimilar<\/strong> of <strong>Amgen&#8217;s Xgeva (denosumab)<\/strong>. The expanded approval authorizes Denosu for the treatment of <strong>solid tumor bone metastasis<\/strong> and <strong>multiple myeloma<\/strong> to <strong>delay or reduce the risk of skeletal-related events<\/strong> (SREs), including pathological fractures, spinal cord compression, bone radiation, or bone surgery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Second indication expansion for approved biosimilar<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Denosu (denosumab biosimilar)<\/td><\/tr><tr><td><strong>Reference Product<\/strong><\/td><td>Amgen&#8217;s Xgeva (denosumab)<\/td><\/tr><tr><td><strong>New Indications<\/strong><\/td><td>Solid tumor bone metastasis; multiple myeloma<\/td><\/tr><tr><td><strong>Therapeutic Objective<\/strong><\/td><td>Delay\/reduce skeletal-related events (SREs)<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>First Xgeva biosimilar approved in China<\/td><\/tr><tr><td><strong>Initial Approval<\/strong><\/td><td>March 2024 \u2013 giant cell tumor of bone<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-profile-amp-clinical-significance\">Therapeutic Profile &amp; Clinical Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-skeletal-related-events-prevention\">Skeletal-Related Events Prevention<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Population:<\/strong> Patients with bone metastases from solid tumors and multiple myeloma<\/li>\n\n\n\n<li><strong>Clinical Need:<\/strong> High risk of debilitating SREs significantly impacting quality of life and survival<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Denosumab inhibits RANK ligand, reducing osteoclast-mediated bone destruction<\/li>\n\n\n\n<li><strong>Efficacy Endpoint:<\/strong> Prevention of pathological fractures, spinal cord compression, need for bone radiation\/surgery<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-expanded-indication-impact\">Expanded Indication Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Reach:<\/strong> Millions of additional patients eligible for treatment beyond initial giant cell tumor indication<\/li>\n\n\n\n<li><strong>Treatment Paradigm:<\/strong> Provides cost-effective alternative to originator Xgeva in high-volume oncology settings<\/li>\n\n\n\n<li><strong>Healthcare Economics:<\/strong> Significant potential savings for China&#8217;s healthcare system in managing bone complications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-commercial-strategy\">Market Context &amp; Commercial Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-biosimilar-landscape-in-china\">Biosimilar Landscape in China<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Xgeva Market Size:<\/strong> Estimated at RMB 1.2 billion (USD 175 million) annually in China<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Biosimilars typically priced 30-50% below originator products<\/li>\n\n\n\n<li><strong>Reimbursement Status:<\/strong> Expected inclusion in provincial reimbursement formularies following indication expansion<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> First-mover advantage as China&#8217;s inaugural Xgeva biosimilar<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-patient-population-analysis\">Patient Population Analysis<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Annual Incidence in China<\/th><th>Treatment Duration<\/th><th>Market Potential<\/th><\/tr><\/thead><tbody><tr><td><strong>Solid Tumor Bone Metastasis<\/strong><\/td><td>~300,000 new cases<\/td><td>Chronic (ongoing)<\/td><td>High volume, sustained revenue<\/td><\/tr><tr><td><strong>Multiple Myeloma<\/strong><\/td><td>~25,000 new cases<\/td><td>Extended treatment<\/td><td>Premium pricing opportunity<\/td><\/tr><tr><td><strong>Giant Cell Tumor (Original)<\/strong><\/td><td>~2,000 cases<\/td><td>Limited duration<\/td><td>Orphan drug positioning<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The indication expansion transforms Denosu from an orphan drug into a mainstream oncology product with significant commercial potential.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-mabwell-bioscience\">Strategic Implications for Mabwell Bioscience<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Validation:<\/strong> Demonstrates successful biosimilar development capabilities and regulatory expertise<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Expands beyond niche giant cell tumor market to high-volume oncology indications<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> Establishes dominant position in China&#8217;s denosumab biosimilar segment<\/li>\n\n\n\n<li><strong>International Potential:<\/strong> Success in China may support global regulatory filings and partnership opportunities<\/li>\n<\/ul>\n\n\n\n<p>&#8220;This second NMPA approval significantly expands Denosu&#8217;s patient reach and therapeutic impact,&#8221; said Dr. Chen Min, CEO of Mabwell Bioscience. &#8220;As China&#8217;s first Xgeva biosimilar, Denosu now offers millions of patients with bone metastases and multiple myeloma access to this critical therapy at a more affordable price point, while maintaining the same efficacy and safety profile as the reference product.&#8221;<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market potential, regulatory approvals, and commercial expectations. Actual results may differ due to risks including market adoption rates, pricing pressures, competitive dynamics, and healthcare policy changes in China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688062_20260416_SEX5.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688062_20260416_SEX5.\"><\/object><a id=\"wp-block-file--media-487c5edb-106a-4759-9c74-24454089315e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688062_20260416_SEX5.pdf\">688062_20260416_SEX5<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688062_20260416_SEX5.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-487c5edb-106a-4759-9c74-24454089315e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,43,16,118,15,1129],"class_list":["post-63348","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-amgen","tag-biosimilars","tag-cancer","tag-mabwell-bioscience","tag-product-approvals","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Bioscience Secures Second NMPA Approval for Denosu, China&#039;s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China&#039;s National Medical Products Administration (NMPA) for Denosu, the country&#039;s first biosimilar of Amgen&#039;s Xgeva (denosumab). The expanded approval authorizes Denosu for the treatment of solid tumor bone metastasis and multiple myeloma to delay or reduce the risk of skeletal-related events (SREs), including pathological fractures, spinal cord compression, bone radiation, or bone surgery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63348\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China&#039;s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China&#039;s National Medical Products Administration (NMPA) for Denosu, the country&#039;s first biosimilar of Amgen&#039;s Xgeva (denosumab). The expanded approval authorizes Denosu for the treatment of solid tumor bone metastasis and multiple myeloma to delay or reduce the risk of skeletal-related events (SREs), including pathological fractures, spinal cord compression, bone radiation, or bone surgery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63348\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T13:11:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T13:11:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63348#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63348\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China&#8217;s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma\",\"datePublished\":\"2026-04-16T13:11:06+00:00\",\"dateModified\":\"2026-04-16T13:11:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63348\"},\"wordCount\":520,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Amgen\",\"Biosimilars\",\"Cancer\",\"Mabwell Bioscience\",\"Product approvals\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63348#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63348\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63348\",\"name\":\"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China's First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-16T13:11:06+00:00\",\"dateModified\":\"2026-04-16T13:11:08+00:00\",\"description\":\"Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China's National Medical Products Administration (NMPA) for Denosu, the country's first biosimilar of Amgen's Xgeva (denosumab). The expanded approval authorizes Denosu for the treatment of solid tumor bone metastasis and multiple myeloma to delay or reduce the risk of skeletal-related events (SREs), including pathological fractures, spinal cord compression, bone radiation, or bone surgery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63348#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63348\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63348#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China&#8217;s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China's First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China's National Medical Products Administration (NMPA) for Denosu, the country's first biosimilar of Amgen's Xgeva (denosumab). The expanded approval authorizes Denosu for the treatment of solid tumor bone metastasis and multiple myeloma to delay or reduce the risk of skeletal-related events (SREs), including pathological fractures, spinal cord compression, bone radiation, or bone surgery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63348","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China's First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma","og_description":"Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China's National Medical Products Administration (NMPA) for Denosu, the country's first biosimilar of Amgen's Xgeva (denosumab). The expanded approval authorizes Denosu for the treatment of solid tumor bone metastasis and multiple myeloma to delay or reduce the risk of skeletal-related events (SREs), including pathological fractures, spinal cord compression, bone radiation, or bone surgery.","og_url":"https:\/\/flcube.com\/?p=63348","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-16T13:11:06+00:00","article_modified_time":"2026-04-16T13:11:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63348#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63348"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China&#8217;s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma","datePublished":"2026-04-16T13:11:06+00:00","dateModified":"2026-04-16T13:11:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63348"},"wordCount":520,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Amgen","Biosimilars","Cancer","Mabwell Bioscience","Product approvals","SHA: 688062"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63348#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63348","url":"https:\/\/flcube.com\/?p=63348","name":"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China's First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-16T13:11:06+00:00","dateModified":"2026-04-16T13:11:08+00:00","description":"Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China's National Medical Products Administration (NMPA) for Denosu, the country's first biosimilar of Amgen's Xgeva (denosumab). The expanded approval authorizes Denosu for the treatment of solid tumor bone metastasis and multiple myeloma to delay or reduce the risk of skeletal-related events (SREs), including pathological fractures, spinal cord compression, bone radiation, or bone surgery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63348#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63348"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63348#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Secures Second NMPA Approval for Denosu, China&#8217;s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63348"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63348\/revisions"}],"predecessor-version":[{"id":63352,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63348\/revisions\/63352"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}